Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $61.90 Consensus PT from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been assigned a consensus rating of “Hold” from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $61.90.

Several equities research analysts have recently weighed in on the stock. Benchmark downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Leerink Partners cut shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a report on Tuesday, May 13th. HC Wainwright restated a “buy” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 7th. Finally, Leerink Partnrs downgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 13th.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $53.45 on Friday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm has a fifty day moving average price of $60.39 and a 200 day moving average price of $55.93. Halozyme Therapeutics has a fifty-two week low of $42.01 and a fifty-two week high of $70.51. The firm has a market cap of $6.59 billion, a price-to-earnings ratio of 15.58, a P/E/G ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same quarter in the prior year, the firm earned $0.79 earnings per share. Halozyme Therapeutics’s revenue was up 35.2% on a year-over-year basis. As a group, sell-side analysts expect that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 503 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now directly owns 33,108 shares of the company’s stock, valued at approximately $2,120,567.40. The trade was a 1.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,697 shares of company stock valued at $1,276,552 over the last ninety days. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in HALO. Isthmus Partners LLC grew its holdings in shares of Halozyme Therapeutics by 2.5% in the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock valued at $439,000 after purchasing an additional 169 shares in the last quarter. OneDigital Investment Advisors LLC grew its holdings in shares of Halozyme Therapeutics by 1.7% in the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock valued at $649,000 after purchasing an additional 175 shares in the last quarter. Park Place Capital Corp grew its holdings in shares of Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 182 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares in the last quarter. Finally, Xponance Inc. grew its holdings in shares of Halozyme Therapeutics by 1.1% in the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock valued at $1,190,000 after purchasing an additional 198 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.